At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed squamous or non-squamous cell carcinoma of the cervix with advanced, persistent, or recurrent disease and documented progression
- ✓Not amenable to curative therapy
- ✓At least one unidimensionally measurable lesion ≥20 mm by conventional imaging or ≥10 mm by spiral CT
- ✓Age 18 and over
- ✕Pregnant or nursing
- ✕Other invasive malignancy within past 5 years except nonmelanoma skin cancer
- ✕Active infection requiring antibiotics
- ✕Uncontrolled seizure disorder or active neurological disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Limited Access Phase II Trial of Cetuximab (C225, NSC #714692) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
In Brief
A Phase 2 clinical trial evaluating cetuximab and cisplatin for Cervical Cancer. Completed, enrolled 76 participants across 18 sites.
Detailed Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also help cisplatin work better by making tumor cells more sensitive to the drug. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cetuximab together with cisplatin may be a better way to block tumor growth. PURPOSE: This phase II trial is studying how well giving cetuximab together with cisplatin works in treating patients with advanced, persistent, or recurrent cervical cancer.